Cardiac resynchronization therapy for prevention of heart failure events in elderly patients with left ventricular dysfunction
- PMID: 23190070
- DOI: 10.1586/erc.12.120
Cardiac resynchronization therapy for prevention of heart failure events in elderly patients with left ventricular dysfunction
Abstract
Heart failure (HF) due to left ventricular (LV) systolic dysfunction contributes significantly to cardiovascular morbidity and is a major cause of mortality throughout the world. Its prevalence is increasing as the population ages. Age-related structural and functional changes of the heart in combination with multiple coexisting comorbid conditions significantly reduce cardiovascular reserve capacity and increase the risks of developing symptomatic HF in the elderly. Cardiac resynchronization therapy (CRT) has been demonstrated to reduce HF-related hospitalization as well as mortality and has become an important part of treatment for qualified patients with advanced HF. More recent studies showed a significant reduction in the risk of HF and mortality among CRT recipients with asymptomatic and mildly symptomatic HF (New York Heart Association functional class I–II), LV systolic dysfunction and widened QRS complex, supporting the notion that CRT may prevent or delay disease progression. Although data on the benefit of preventive CRT in the elderly are limited to retrospective subgroup analyses with relatively small numbers of elderly patients, accumulating data suggest that CRT confers similar or greater clinical benefit among elderly patients compared with their younger counterparts. As the proportion of elderly patient with LV systolic dysfunction is increasing dramatically, further research is warranted to confirm these possible clinically beneficial effects of CRT in this population.
Similar articles
-
Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.J Am Coll Cardiol. 2009 Nov 10;54(20):1837-46. doi: 10.1016/j.jacc.2009.08.011. Epub 2009 Oct 1. J Am Coll Cardiol. 2009. PMID: 19800193 Clinical Trial.
-
Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).Eur Heart J. 2011 Jul;32(13):1631-9. doi: 10.1093/eurheartj/ehq408. Epub 2010 Nov 25. Eur Heart J. 2011. PMID: 21112898 Clinical Trial.
-
Effectiveness of implantable cardioverter defibrillators and cardiac resynchronization therapy in heart failure.Heart Fail Clin. 2013 Jan;9(1):59-77. doi: 10.1016/j.hfc.2012.09.006. Epub 2012 Oct 13. Heart Fail Clin. 2013. PMID: 23168318 Review.
-
Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.Am J Cardiol. 2007 Jul 1;100(1):90-3. doi: 10.1016/j.amjcard.2007.02.058. Epub 2007 May 15. Am J Cardiol. 2007. PMID: 17599447 Clinical Trial.
-
Cardiac resynchronization therapy: device-based medicine for heart failure.J Card Surg. 2004 May-Jun;19(3):270-4. doi: 10.1111/j.0886-0440.2004.04081.x. J Card Surg. 2004. PMID: 15151661 Review.
Cited by
-
Comparative effects of left bundle branch area pacing, His bundle pacing, biventricular pacing in patients requiring cardiac resynchronization therapy: A network meta-analysis.Clin Cardiol. 2022 Feb;45(2):214-223. doi: 10.1002/clc.23784. Epub 2022 Feb 7. Clin Cardiol. 2022. PMID: 35128691 Free PMC article.
-
Self-powered cardiovascular electronic devices and systems.Nat Rev Cardiol. 2021 Jan;18(1):7-21. doi: 10.1038/s41569-020-0426-4. Epub 2020 Sep 7. Nat Rev Cardiol. 2021. PMID: 32895536 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous